Dashboard
Manage Tickers

CELC


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-77
HC Wainwright & Co. Maintains Buy on Celcu...
10/22/2025 11:49:48

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

ww-international-replimune-group-datavault-ai-grail-and-other-big-stocks-moving-higher-on-monday
WW International, Replimune Group, Datavau...
10/20/2025 14:13:22

dow-jumps-over-200-points-cleveland-cliffs-shares-jump-after-q3-results
Dow Jumps Over 200 Points; Cleveland-Cliff...
10/20/2025 13:49:54

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
10/20/2025 12:08:17

needham-reiterates-buy-on-celcuity-maintains-70-price-target
Needham Reiterates Buy on Celcuity, Mainta...
10/20/2025 10:10:53

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

reported-saturday-celcuity-presented-phase-1-data-at-esmo-2025-showing-gedatolisib-plus-darolutamide-delivers-91-month-median-rpfs-in-mcrpc-with-favorable-safety-profile-and-no-trae-related-discontinuations
Reported Saturday, Celcuity Presented Phas...
10/20/2025 08:18:12

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%No patients di...

reported-saturday-celcuity-announces-phase-3-viktoria-1-data-gedatolisib-triplet-reduces-risk-of-progression-or-death-by-76-in-hrher2--pik3ca-wild-type-advanced-breast-cancer
Reported Saturday, Celcuity Announces Phas...
10/20/2025 08:16:32

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of...

needham-reiterates-buy-on-celcuity-maintains-70-price-target
Needham Reiterates Buy on Celcuity, Mainta...
10/03/2025 10:38:42

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

celcuity-to-present-phase-3-viktoria-1-breast-cancer-data-in-late-breaking-oral-session-at-esmo-2025
Celcuity To Present Phase 3 VIKTORIA-1 Bre...
09/22/2025 13:17:34

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

guggenheim-initiates-coverage-on-celcuity-with-buy-rating-announces-price-target-of-110
Guggenheim Initiates Coverage On Celcuity ...
09/22/2025 10:57:45

Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...

celcuitys-nda-for-gedatolisib-in-hrher2--breast-cancer-accepted-into-fdas-real-time-oncology-review-program
Celcuity's NDA For Gedatolisib In HR+/HER2...
08/27/2025 20:14:22

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-66
HC Wainwright & Co. Maintains Buy on Celcu...
08/18/2025 10:34:59

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

needham-maintains-buy-on-celcuity-lowers-price-target-to-70
Needham Maintains Buy on Celcuity, Lowers ...
08/15/2025 10:05:13

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.

celcuity-q2-adj-eps-093-misses-088-estimate
Celcuity Q2 Adj. EPS $(0.93) Misses $(0.88...
08/14/2025 20:03:43

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.93) per share which missed the analyst consensus estimate of $(0.88) by...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

insights-into-celcuitys-upcoming-earnings
Insights into Celcuity's Upcoming Earnings
08/13/2025 14:02:18

celcuity-prices-175m-in-2750-convertible-notes-and-common-stock-at-38-per-share-to-raise-2487m-for-oncology-pipeline
Celcuity Prices $175M In 2.750% Convertibl...
07/30/2025 10:38:25

leerink-partners-maintains-outperform-on-celcuity-raises-price-target-to-60
Leerink Partners Maintains Outperform on C...
07/28/2025 21:14:34

Leerink Partners analyst Andrew Berens maintains Celcuity (NASDAQ:CELC) with a Outperform and raises the price target from $...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION